Artiva Biotherapeutics (ARTV) Registration Filing summary

Company overview and business model

• Clinical-stage biotech focused on developing allogeneic, off-the-shelf NK cell-based therapies for autoimmune diseases and cancers.

• Lead product, AlloNK, is a non-genetically modified NK cell therapy, evaluated in combination with B-cell targeted mAbs in lupus nephritis and other autoimmune indications.

• Proprietary manufacturing platform enables large-scale, cryopreserved NK cell production from cord blood, supporting scalability and cost efficiency.

• Strategic partnerships with GC Cell (manufacturing/technology) and Affimed (combination therapy in oncology).

• Mission to provide effective, safe, and accessible cell therapies for high unmet need conditions.

Financial performance and metrics

• No product sales to date; revenue derived from collaboration and license agreements.

• 2023 revenue: $33.5M (mainly from Merck collaboration, now terminated); net loss: $28.7M; accumulated deficit: $195.3M as of March 31, 2024.

• Cash, cash equivalents, and short-term investments: $62.1M as of March 31, 2024.

• Operating expenses in 2023: $64.2M, primarily R&D ($50.3M) and G&A ($13.9M).

• Substantial doubt about ability to continue as a going concern without additional capital; expects to continue incurring losses for the foreseeable future.

Use of proceeds and capital allocation

• Net proceeds from IPO, combined with existing cash, will fund clinical development of AlloNK, additional discovery/preclinical work, headcount, manufacturing, working capital, and general corporate purposes.

• May use a portion for in-licensing, acquisitions, or investments in complementary businesses or technologies.

• Proceeds expected to fund operations through a specified period, but additional capital will be needed for full development and commercialization.